- Precision
medicine, AI among top healthcare investment trends for 2020
- Predictive
Oncology is data, AI-driven precision medicine company with an exclusive
database of patient samples
- Market
estimates for precision medicine expected to reach $84.6 billion by 2024
Precision medicine and artificial intelligence rank high on
the list of top investment-focused healthcare trends, according to a
recent Emagine article (http://ibn.fm/jALh4). Both are key areas of focus for Predictive Oncology Inc. (NASDAQ: POAI), a leading data and
artificial-intelligence-driven precision medicine company. In an arena where
data is king and artificial intelligence is increasingly gravitating to the
spotlight, POAI is uniquely positioned with its historic database of patient
samples and its cutting-edge AI-powered platform.
“We’ll see more progress in the next 10 years than we’ve
seen in the past 50,” stated industry analyst Bill Gadless, who compiled the
list of industry trends after attending the 38th annual J.P. Morgan Healthcare
Conference. Gadless noted that the hot trends focus on “continuing to save,
extend and improve lives.”
The annual conference, the largest and most informative
healthcare investment symposium in the industry, brings together industry
leaders, innovative technology creators, emerging fast-growth companies and
other members of the investment community. Precision medicine received
significant interest with its focus on matching up patients with precisely
targeted treatments tailored to their unique genetic makeup. At the same time,
AI was highlighted as an emerging and increasingly significant tool for use in
clinical trials, practice management and digital-health diagnostics.
Emerging as one to watch in the industry, Predictive
Oncology is bringing its cutting-edge technology to help pharmaceutical,
diagnostic and biotech companies develop new therapies. Through its subsidiary
Helomics, a leader in AI and functional precision medicine, POAI harnesses rich
patient information gleaned from its PDx tumor profiling platform with the
potential to revolutionize cancer research as it is seen today. Through the
development of AI-driven predictive models that indicate how tumors respond to
drugs, POAI will support clinicians in making decisions to individualize
patient treatment. Additionally, these AI-driven models, together with the PDx
tumor profiling platform can accelerate research into new targeted therapies.
Drug development for cancer treatment is a costly and
time-intensive endeavor – the average drug takes upwards of 10 years and $3
billion to produce – and as technology plays an ever-increasing role in driving
medicine, researchers and clinicians are discovering the significant potential
of patient-derived PDx models in understanding the activity of potential new
drugs on tumors. These models harness cancer cells from patient tumors to
create a truly patient-centric future of precision medicine.
As a striking example of this intersection of research and
technology, POAI’s Helomics clinical PDx platform compares the drug response
and genomic profile of a patient’s own tumor grown in the lab with its database
of over 150,000 existing tumor profiles to help recommend the best treatment
for that patient. As additional patient samples are tested, they continue to
enhance the database improving the recommendations. Leveraging the rich data in
this database with AI to create AI-driven predictive models provides a valuable
tool for pharmaceutical companies and researchers, offering a model that
embodies actual drug response of cancer patients’ individual tumors and their
outcomes (i.e. survival). This ability to build AI-driven predictive models of
cancer puts the company in a powerful position to offer actionable insights to
pharmaceutical companies much more quickly than its competitors.
According to Mordor Intelligence Inc., oncology is expected
to have the largest share of the precision medicine market in excess of 30%
over other segments, along with a CAGR of 10.3% from 2018 to 2024 (http://ibn.fm/1Uv7p). Eyeing the
projected overall market estimate of $84.6 billion by 2024, POAI is positioning
itself to capture a considerable portion of this growth potential with its
unique proprietary technology.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
